In patients with type 2 diabetes mellitus, both sodium-glucose cotransporter 2 inhibitors (SGLT2is) and glucagon-like peptide receptor agonists (GLP-1 RAs) have been shown to significantly improve cardiovascular and kidney outcomes independent of their effect on glycemia. Here, SLC5A2 is linked to diabetes mellitus.